Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
TBPH Total Debt
Short-term and long-term borrowings combined.
Theravance Biopharma, Inc.NASDAQ: TBPH
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 52.2% from a year ago
Total debt stood at $73.3M at the end of Q1 FY2026, up 52.2% from a year earlier and down 2.9% from the prior quarter. Over 3 fiscal years it compounded at +13.1% a year.
Context
- Total debt amounted to 15.5% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +52.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 75.5M USD
- Year-over-year change
- +51.5%
- 4-year CAGR
- -42.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.5M | +51.5% |
| FY2024 | 2024-12-31 | 49.82M | +1.3% |
| FY2023 | 2023-12-31 | 49.16M | -5.8% |
| FY2022 | 2022-12-31 | 52.16M | -92.2% |
| FY2021 | 2021-12-31 | 669.52M | — |
Total Debt vs competitors
How TBPH compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +52.2% is the 3rd highest of 9, against a peer median of -0.6%.
- Total debt amounts to 15.5% of total assets for TBPH, versus a peer median of 7.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $251.84M USD | +106.8% | +65.2% | 47.2% | |
| Mar 2026 | €209.72M EUR | -0.7% | +10.8% | 56.3% | |
| Mar 2026 | $95.58M USD | -0.5% | +13.5% | 9.3% | |
| Dec 2025 | $76.35M USD | +0.4% | +32.4% | 22.9% | |
| Mar 2026 | $73.3M USD | +52.2% | +13.1% | 15.5% | |
| Mar 2026 | $39.06M USD | -6.7% | -5.9% | 5.3% | |
| Mar 2026 | $5.7M USD | -6.9% | +30.4% | 1.4% | |
| Mar 2026 | $673K USD | -43.1% | +48.3% | 0.2% | |
| Mar 2026 | $419K USD | +203.6% | -53.5% | 0.1% | |
| Peer median (excluding TBPH) | — | -0.6% | +21.9% | 7.3% | |
Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89.96M | 298.17M | 39.55M | 37.8M | 167.81M |
| Short-term Investments | 83.51M | 29.31M | 62.88M | 50.55M | 147.55M |
| Net Receivables | 57.6M | 16.79M | 17.47M | 68.44M | 95.54M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.56M | 7.68M | 11.6M | 4.2M | 7.56M |
| Total Current Assets | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M |
| Property, Plant & Equipment (Net) | 53.35M | 52M | 45.36M | 35.77M | 30.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 68.37M | 0 | 0 | 0 | 14.35M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.23M | 201.94M | 203.1M | 157.32M | 22.5M |
| Total Non-current Assets | 124.95M | 253.94M | 248.46M | 193.09M | 67.11M |
| Total Assets | 374.82M | 607.4M | 382M | 354.16M | 485.57M |
| Account Payables | 3.1M | 1.55M | 1.52M | 2.24M | 2.57M |
| Short-term Debt | 17.44M | 0 | 0 | 0 | 10.95M |
| Tax Payables | 0 | 0 | 0 | 5.85M | 0 |
| Deferred Revenue | 98K | 24K | 0 | 0 | 0 |
| Other Current Liabilities | 25.15M | (24K) | 12.88M | 0 | 6.91M |
| Total Current Liabilities | 58.59M | 28.72M | 24.77M | 32.09M | 38.3M |
| Long-term Debt | 599.39M | 0 | 0 | 0 | 32.8M |
| Deferred Tax Liabilities | 240K | 0 | 0 | 0 | 85.68M |
| Deferred Revenue (Non-current) | 310K | 192K | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.18M | 91.29M | 99M | 107.42M | 313K |
| Total Non-current Liabilities | 654.81M | 136.89M | 144.24M | 146.53M | 150.55M |
| Total Liabilities | 713.39M | 165.6M | 169M | 178.62M | 188.85M |
| Common Stock | 1K | 1K | 0 | 0 | 1K |
| Retained Earnings | (1.73B) | (853.91M) | (909.1M) | (965.52M) | (859.63M) |
| Accumulated OCI | (0) | (15K) | (65K) | 7K | 61K |
| Other Stockholders Equity | 0 | 0 | (0) | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (338.57M) | 441.8M | 213M | 175.55M | 296.72M |
| Total Debt | 669.52M | 52.16M | 49.16M | 49.82M | 75.5M |
| Net Debt | 579.56M | (246.01M) | 9.61M | 12.02M | (92.31M) |
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.